NCMP-02. MYASTHENIA GRAVIS INDUCED BY AVELUMAB

Monoclonal antibodies targeting PD- 1 (nivolumab and pembrolizumab) and PD-L1 (avelumab, atezolizumab, and durvalumab) are FDA approved for the treatment of metastatic cancers. Immune-related adverse events (irAEs) are autoimmune diseases which occur following treatment with PD-1 and PD-L1 inhibitor...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Neuro Oncol
Prif Awduron: Yuen, Carlen, Fleming, Gini, Soliven, Betty, Myers, Michael, Rezania, Kourosh
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2019
Pynciau:
Neurological Complications of Cancer and Cancer Therapy
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847032/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.748
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg